null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

Pre-revenue medtech startup; likely minimal long-term debt, funded primarily via venture equity (~$300M+ raised); a 20% rate rise marginally impacts cost of any convertible notes or credit facilities

Low direct sensitivity; primary risk is higher discount rates compressing VC valuations and extending runway requirements for next equity raise

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Taiwan/Asia semiconductor fabs for insulin pump microcontrollers; 2) China-based battery and sensor component manufacturing

Primarily US-focused (FDA cleared 2023); minimal international revenue yet; currency devaluation exposure in EU (EUR), Canada (CAD), UK (GBP) upon CE/Health Canada approval

Overwhelmingly US-domestic revenue base; EU and Canada are next target markets; sovereign currency devaluation risk is currently immaterial but will grow post-international launch

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on Dexcom CGM sensor integration and Abbott CGM APIs; iLet system's closed-loop algorithm is non-substitutable without significant redesign

Medical device hardware/software hybrid; cloud infrastructure disruption would impair iLet Bionic Pancreas remote monitoring and algorithm update delivery, risking FDA compliance obligations

Consumables and supply revenue model; cloud termination would not halt device function but would break data logging, telemedicine integration, and OTA firmware updates

High API coupling to Dexcom G6/G7 and Abbott FreeStyle CGM data streams; FDA clearance tied to specific sensor pairings, making substitution a multi-year regulatory re-clearance process

Not applicable; revenue model is medical device sales and consumables, not an investment contract; Howey Test risk is negligible

Very High

Moderate-to-high; continuous glucose and insulin dosing data is sensitive health data subject to HIPAA, GDPR (upon EU launch), and CCPA; cloud storage jurisdiction and PHI handling require strict compliance

Low currently; niche closed-loop insulin delivery market; potential future scrutiny if partnerships with Dexcom/Lilly create exclusionary bundling, but market share is modest

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Recurring consumables (infusion sets, cartridges, CGM supplies) estimated 60-70% of long-term revenue; upfront hardware sales ~30-40%; strong recurring mix once installed base scales

Hardware device sale + recurring consumable supply subscription/refill model; potential for software-as-a-medical-device (SaMD) licensing fees as algorithm expands

iLet device ~$4,500 MSRP; consumables ~$300-400/month; insurance reimbursement-dependent pricing creates vulnerability if CMS or major payers tighten coverage criteria

Moderate; clinical superiority of fully automated bihormonal dosing justifies premium, but payer negotiation and competitive pressure from Medtronic/Insulet constrain independent pricing power

55.4% Gross Margin (Strong (40-60%))

Low free-rider risk; prescription-only medical device with no open-source workaround; however, payer non-coverage can force patient churn to covered competitor devices

Largely headcount-sublinear at scale; manufacturing scales with contract manufacturing partners; software/algorithm improvements are fixed-cost leverageable; clinical and regulatory teams grow modestly

Marginal cost of growth primarily driven by hardware COGS and consumables manufacturing; software algorithm deployment has near-zero marginal cost per additional patient

null

CAC dominated by endocrinologist detailing and clinical evidence dissemination; at 10x scale, CAC should decline as clinical guidelines adopt closed-loop standard of care

Weak direct network effects; real-world outcomes data improves algorithm over time (data network effect), but individual device value is independent of user base size

AI displacement risk is low near-term; the iLet algorithm IS the AI/ML core product; risk is competitive AI algorithm improvement by Medtronic, Insulet, or Tidepool outpacing Beta Bionics R&D

High recession resistance; Type 1 diabetes is a life-sustaining chronic condition; insulin delivery devices are non-discretionary, though payer mix shifts could slow new patient onboarding

Type 1 diabetes patients (pediatric and adult) requiring automated insulin delivery; ~1.9M US T1D patients are the primary addressable segment

Type 2 diabetes patients on intensive insulin therapy; secondary segment with larger addressable population but lower urgency and payer reimbursement hurdles

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

5.3% CapEx / Revenue (Moderate-CapEx)

0001674632

BBNX